Letrozole is an inhibitor of aromatase that prevents the formation of estrogens; it is clinically used to treat hormone-responsive breast cancer and infertility and to terminate pregnancy. Letrozole exhibits anticancer chemotherapeutic and anti-estrogenic activities. In vivo, letrozole increases secretion of luteinizing hormone (LH), lengthens the follicular dominance period, and delays subsequent follicular waves.
| Cas No. | 112809-51-5 |
|---|---|
| Purity | ≥98% |
| Formula | C17H11N5 |
| Formula Wt. | 285.30 |
| Chemical Name | 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile |
| IUPAC Name | 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile |
| Synonym | Femara |
| Melting Point | 181-183°C |
| Solubility | Soluble in dichloromethane, DMSO (100 mM). Slightly soluble in ethanol. practically insoluble in water. Soluble in chloroform, methanol. |
| Appearance | White Crystal Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | L1878 MSDS PDF |
|---|---|
| Info Sheet | L1878 Info Sheet PDF |
Lee VC, Gao J, Lee KF, et al. The effect of letrozole with misoprostol for medical termination of pregnancy on the expression of steroid receptors in the placenta. Hum Reprod. 2013 Nov;28(11):2912-9. PMID: 23980056.
Tomao F, Spinelli G, Vici P, et al. Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther. 2011 Aug;11(8):1253-63. PMID: 21916579.
Yapura J, Mapletoft RJ, Pierson R, et al. A bovine model for examining the effects of an aromatase inhibitor on ovarian function in women. Fertil Steril. 2011 Aug;96(2):434-438.e3. PMID: 21696721.
